INSULIN-SECRETION, GASTRIC-INHIBITORY POLYPEPTIDE (GIP) AND GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AFTER ORAL GLUCOSE IN CIRRHOSIS

被引：0
|
作者：
KRUSZYNSKA, Y
GHATEI, M
BLOOM, S
MCINTYRE, N
机构：
来源：
DIABETES | 1993年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A174 / A174
页数：1
相关论文
共 50 条
  • [41] Normal secretion of the glucagon-like peptide-1 (GLP-1) during gestational diabetes mellitus
    Lencioni, C.
    Lupi, R.
    Resi, V.
    Bertolotto, A.
    Romero, F.
    Ghio, A.
    Volpe, L.
    Del Prato, S.
    Marchetti, P.
    Di Cianni, G.
    DIABETOLOGIA, 2009, 52 : S454 - S454
  • [42] Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia
    M. Toft-Nielsen
    S. Madsbad
    J. J. Holst
    Diabetologia, 1998, 41 : 1180 - 1186
  • [43] Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia
    Toft-Nielsen, M
    Madsbad, S
    Holst, JJ
    DIABETOLOGIA, 1998, 41 (10) : 1180 - 1186
  • [44] Characterization of chimeric gastric inhibitory polypeptide (GIP) and glucagonlike peptide-1 (GLP-1) receptor proteins.
    Boylan, MO
    Wolfe, MM
    GASTROENTEROLOGY, 1996, 110 (04) : A1060 - A1060
  • [45] The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
    Fisman, Enrique Z.
    Tenenbaum, Alexander
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [46] Differential signaling in response to glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) stimulation in the vasculature: modulation of osteopontin expression
    Berglund, Lisa M.
    Lyssenko, Valeriya
    Kotova, Olga
    Zetterqvist, Anna V.
    Gottsater, Anders
    Vaag, Allan
    Goncalves, Isabel
    Groop, Leif
    Gomez, Maria F.
    FASEB JOURNAL, 2011, 25
  • [47] Glucagon-like peptide 1 (GLP-1)
    Mueller, T. D.
    Finan, B.
    Bloom, S. R.
    D'Alessio, D.
    Drucker, D. J.
    Flatt, P. R.
    Fritsche, A.
    Gribble, F.
    Grill, H. J.
    Habener, J. F.
    Holst, J. J.
    Langhans, W.
    Meier, J. J.
    Nauck, M. A.
    Perez-Tilve, D.
    Pocai, A.
    Reimann, F.
    Sandoval, D. A.
    Schwartz, T. W.
    Seeley, R. J.
    Stemmer, K.
    Tang-Christensen, M.
    Woods, S. C.
    DiMarchi, R. D.
    Tschoep, M. H.
    MOLECULAR METABOLISM, 2019, 30 : 72 - 130
  • [48] Racial differences in glucagon-like peptide-1 (GLP-1) and insulin secretion during oral glucose tolerance test in obese non-diabetic subjects
    Velasquez-Mieyer, PA
    Umpierrez, GE
    Lustig, RH
    Cashion, AK
    Cowan, PA
    Burghen, GA
    DIABETES, 2002, 51 : A362 - A362
  • [49] The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
    Enrique Z. Fisman
    Alexander Tenenbaum
    Cardiovascular Diabetology, 20
  • [50] Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes
    Frias, Juan P.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2020, 15 (06) : 379 - 394
12345